Research progress on prevention and treatment of invasive fungal diseases in patients with hematological malignancies

Abstract

The incidence of invasive fungal disease (IFD) is high in patients with hematological malignancies, including those with acute myeloid leukemia(AML)/myelodysplastic syndrome(MDS), and those receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). IFD is an important prognostic factor in patients with hematological malignancies. IFD is difficult to diagnose, and the efficacy of treatment is poor. Therefore, antifungal treatment begins with prevention. At present, there are still controversies about the clinical indications, drugs, administration time and efficacy of IFD chemoprevention. This article intends to review the research progress on the epidemiology and risk factors of IFD, as well as the clinical outcomes of antifungal agents for antifungal prophylaxis in patients with hematological malignancies. Key words: Antifungal agents; Hematologic neoplasms; Epidemiologic studies; Chemoprevention; Invasive fungal disease